Intercept Pharma (ICPT): Symphony Health Indicates Above Consensus Ocaliva Sales - Wedbush

October 11, 2016 7:49 AM EDT
Get Alerts ICPT Hot Sheet
Price: $131.17 --0%

Rating Summary:
    17 Buy, 3 Hold, 5 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 15 | Down: 22 | New: 6
Trade ICPT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) and sees growing Ocaliva sales and multiple catalysts in the next 6-18 months.

Symphony Health (SH) estimated just over $5 million for Q3 OCA sales— above consensus of $3.5 million. Based on the monthly estimates for OCA sales for PBC, the analyst estimates Q3 OCA sales of at least $5 million, ahead of the Thomson consensus of ~$3.5 million (range $1.6 million to $7.2 million).

There is no change to estimates at this time since Ocaliva was only launched in June and there is not a consistent capture rate for the Symphony Health monthly estimates compared with reported sales.

No change to the price target of $239.

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $154.00 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Liana Moussatos

Add Your Comment